Actinium Pharmaceuticals, Inc. current report, 27 March 2017

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Actinium Pharmaceuticals, Inc. on March 28, 2017. The report discloses the appointment of a new director to the Company's Board of Directors.

Key Financial Metrics

The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and executive compensation arrangements.

Material Changes

The primary material change reported is the appointment of Ajit S. Shetty, Ph.D., as a Class III director on March 28, 2017. Dr. Shetty brings 36 years of leadership experience in the pharmaceutical industry, including former roles as President and Managing Director at Janssen Pharmaceutica and head of Enterprise Supply Chain at Johnson & Johnson.

Compensation and Governance Details

  • Compensation: Dr. Shetty will receive an annual cash compensation of $40,000, payable in quarterly installments.
  • Equity Grant: He was granted 75,000 stock options with a 10-year term. The exercise price is set at the share price on March 28, 2017.
  • Vesting Schedule: 28% of the options vest on the 12-month anniversary of the commencement date, with the remaining balance vesting at 2% per month thereafter.
  • Term: Dr. Shetty serves until resignation, removal, or election of a successor. He is classified as a Class III director, up for election at the 2019 annual shareholders meeting.
  • Agreements: The appointment includes a Director Agreement, an Indemnity Agreement, and a Confidential Information and Invention Assignment Agreement.

Investor Verification Checklist

  • Verify the stock price on March 28, 2017, to determine the exercise price of the 75,000 options granted.
  • Review the full text of the Director Agreement (Exhibit 10.1) for additional terms not summarized in the filing.
  • Confirm Dr. Shetty's current status on the Board and any subsequent changes to his compensation or tenure.
  • Check for any related party transactions that may have been disclosed in subsequent filings.